医保优势计划与传统按服务付费对冠心病患者管理差异
本研究基于PINNACLE注册表观察性回顾性队列,比较35 563例医保优势计划(MA)与172 732例传统按服务付费(FFS)冠心病患者的循证二级预防治疗及中间结局。MA患者接受β受体阻滞剂、ACEI/ARB、他汀及三者联合治疗的比例均更高,校正后上述差异仍显著。但两组在血压和低密度脂蛋白胆固醇等中间结局上无显著差异。
要点
- MA冠心病患者接受β受体阻滞剂(80.6% vs 78.8%)、ACEI/ARB(70.7% vs 65.1%)、他汀(68.4% vs 64.5%)的比例均高于FFS。
- 两组在收缩压、舒张压及低密度脂蛋白胆固醇等中间结局上无显著差异。
核心结论
- MA冠心病患者比FFS患者有更多合并症,且更可能接受循证二级预防治疗,但未转化为中间结局差异。
- MA计划可能改善基于过程的质量指标,但对患者结局改善作用有限。
研究设计与样本
- 观察性回顾性队列研究,数据来自2013年1月1日至2014年5月1日PINNACLE注册表中心脏科诊所的冠心病患者。
- 纳入35 563例MA患者和172 732例FFS患者,年龄18岁以上,数据分析时间为2018年3月至7月。
主要发现
- MA患者平均年龄76.7(7.6)岁,男性占56.8%;FFS患者平均年龄77.5(8.0)岁,男性占57.9%。
- MA患者更年轻、白人比例更低、女性比例更高,且心衰、糖尿病和慢性肾脏病比例更高。
- 两组在收缩压、舒张压和低密度脂蛋白胆固醇等中间结局上无显著差异。
临床怎么用
- 在冠心病二级预防中,可参考MA计划对过程质量指标的促进经验,但需关注其未改善中间结局的现实。
- 对合并症较多的MA冠心病患者,应持续优化循证药物处方,同时监测血压和血脂等中间结局。
局限性
- 研究为观察性回顾性设计,可能存在未测量混杂。
- 数据来自PINNACLE注册表参与诊所,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: One-third of Medicare beneficiaries are enrolled in Medicare Advantage (MA), Medicare's private plan option. Medicare Advantage incentivizes performance on evidence-based care, but limited information exists using reliable clinical data to determine whether this translates into better quality for patients with coronary artery disease (CAD) enrolled in MA compared with those enrolled in traditional fee-for-service (FFS) Medicare. OBJECTIVE: To determine differences in evidence-based secondary prevention treatments and intermediate outcomes among patients with CAD enrolled in MA vs FFS Medicare. DESIGN, SETTING, AND PARTICIPANTS: In this observational, retrospective, cohort study, deidentified data from patients 18 years or older diagnosed as having CAD between January 1, 2013, and May 1, 2014, at cardiology practices participating in the Practice Innovation and Clinical Excellence (PINNACLE) registry were studied, including 35 563 patients enrolled in MA and 172 732 enrolled in FFS Medicare. Data were analyzed from March to July 2018. EXPOSURES: Medicare Advantage enrollment. MAIN OUTCOMES AND MEASURES: Medication prescription patterns among eligible patients and intermediate outcomes, including blood pressure and low-density lipoprotein cholesterol. RESULTS: Of the 35 563 patients with CAD enrolled in MA, 20 193 (56.8%) were male, and the mean (SD) age was 76.7 (7.6) years; of the 172 732 patients with CAD enrolled in FFS Medicare, 100 025 (57.9%) were male, and the mean (SD) age was 77.5 (8.0) years. Patients enrolled in MA were younger, less likely to be white, and more likely to be female and to have heart failure, diabetes, and chronic kidney disease compared with those enrolled in FFS Medicare. Compared with FFS Medicare beneficiaries, MA beneficiaries were more likely to receive secondary prevention treatments, including β-blockers (80.6% vs 78.8%; P < .001), angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (70.7% vs 65.1%; P < .001), and statins (68.4% vs 64.5%; P < .001). Patients enrolled in MA were also more likely to receive all 3 medications when eligible (48.9% vs 40.4%; P < .001). After adjustment, MA beneficiaries had higher odds of receiving guideline-recommended therapy compared with FFS Medicare beneficiaries for β-blockers (odds ratio, 1.10; 95% CI, 1.04-1.17; P = .002), angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (odds ratio, 1.13; 95% CI, 1.08-1.19; P < .001), and all 3 medications (odds ratio, 1.23; 95% CI, 1.001-1.50; P = .047). There were no significant differences in intermediate outcomes between those enrolled in MA and FFS Medicare, including systolic and diastolic blood pressure and low-density lipoprotein cholesterol levels. CONCLUSIONS AND RELEVANCE: Among patients with CAD in the PINNACLE registry, MA beneficiaries had more comorbidities than FFS Medicare beneficiaries and were more likely to receive secondary prevention treatments. However, this did not translate into differences in intermediate outcomes. These findings suggest that MA plans may drive improvements in process-based quality measures for Medicare beneficiaries, although this may have a limited effect on improving patient outcomes over FFS Medicare.
引用
- Figueroa JF, Blumenthal DM, Feyman Y, et al. Differences in Management of Coronary Artery Disease in Patients With Medicare Advantage vs Traditional Fee-for-Service Medicare Among Cardiology Practices. JAMA Cardiol. 2019. PMID: 30785590. doi:10.1001/jamacardio.2019.0007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。